Meet the EAB: Somesh Nigam
ACT would like to welcome Somesh Nigam to our Editorial Advisory Board and introduce him to our readers.
Somesh Nigam, PhD, is Director of Enterprise Architecture in the Pharma R&D IM organization at Johnson & Johnson Pharmaceutical Research and Development. In this role, he leads a group responsible for developing Architecture for strategic IM investments across Pharma R&D.
Somesh Nigam, PhD
Prior to joining Information Management, Somesh was responsible for rolling out EDC (electronic data capture) processes globally as head of the eTrials group within Clinical Operations.
Over the past few years, Somesh has played a leadership role in the strategic development of innovative clinical processes and platforms aimed at improving R&D productivity and efficiency. These include the implementation of a global clinical trials management system (CTMS), a clinical data warehousing/data mining initiative to support proactive safety surveillance, a global clinical trials registry designed for public disclosure of trials, and a new platform for managing health care compliance (HCC).
Recently, he has been active in exploring ways to leverage emerging health care IT platforms including electronic medical records (EMRs) to drive evidence-based Medicine (EMB), personalized medicine, and new knowledge discovery (KD) for the improvement of clinical trials, drug safety, and outcomes research.
Somesh holds a Masters and PhD in Biochemical Engineering from the University of Michigan and an undergraduate degree in Engineering from Indian Institute of Technology. His early career involved the development of large-scale cGMP processes for manufacturing genetically engineered drugs and biologics, including a number of growth factors, monoclonal antibodies, and vaccines. His interests gradually shifted toward clinical operations and informatics as he recognized that inefficiencies inherent in traditional clinical trial processes were playing a key role in declining pharmaceutical R&D productivity. The "engineer" in him was convinced that an informatics-enabled integrative approach utilizing data emerging from preclinical, clinical, and postmarketing realms in concert with advanced analytics, modeling, and simulation techniques was the key to turning around this situation.
Somesh is a frequent speaker at forums sponsored by organizations such as DIA, CDISC, PhRMA, and Clinical Trials Congress. He serves on the Advisory Board for the Department of Chemical Engineering at the University of Michigan and lectures on eClinical technologies in a graduate-level course conducted by the University's Pharmaceutical Engineering Department.
He lives with his wife Shefalika and two children, Vishan and Ruhani, in Princeton, New Jersey.
Somesh Nigam, PhD, Johnson & Johnson Pharmaceutical Research and Development
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
